<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064376</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000315451</org_study_id>
    <secondary_id>CSMC-IRB-4107-01</secondary_id>
    <nct_id>NCT00064376</nct_id>
  </id_info>
  <brief_title>Paricalcitol in Treating Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop&#xD;
      into normal bone marrow cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who&#xD;
      have myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical effects of paricalcitol in patients with myelodysplastic&#xD;
           syndromes.&#xD;
&#xD;
        -  Determine whether this drug can improve RBC, WBC, or platelet counts in these patients.&#xD;
&#xD;
        -  Determine whether this drug can decrease the risk of development of leukemia without&#xD;
           causing undue toxicity in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive oral paricalcitol daily for 4 months in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 8 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2003</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paricalcitol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Clinical diagnosis of myelodysplastic syndromes according to the modified FAB&#xD;
             classification&#xD;
&#xD;
               -  Confirmed by bone marrow aspiration showing blast and promyelocyte count no&#xD;
                  greater than 30% of the bone marrow differential&#xD;
&#xD;
          -  Patients with refractory anemia with ringed sideroblasts are eligible provided there&#xD;
             was no response to a 3-week course of prior high-dose pyridoxine&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  25 to 100&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2.5 mg/dL&#xD;
&#xD;
          -  Calcium normal&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior sensitivity to paricalcitol or any component of its formulation&#xD;
&#xD;
          -  No prior cholecalciferol toxicity&#xD;
&#xD;
          -  No other concurrent acute illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 5 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 5 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior recent surgery allowed, if fully recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 5 weeks since prior megadose vitamins&#xD;
&#xD;
          -  No concurrent cholecalciferol, phosphate, calcium, or cholestyramine&#xD;
&#xD;
          -  No concurrent digoxin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Phillip Koeffler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>H. Phillip Koeffler</investigator_full_name>
    <investigator_title>Director, Medicine / Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

